After H.C. Wainwright and William Blair gave Global Blood Therapeutics (NASDAQ: GBT) a Buy rating last month, the company received another Buy, this time from SunTrust Robinson. Analyst Edward Nash reiterated a Buy rating on Global Blood Therapeutics today and set a price target of $90. The company’s shares opened today at $46.01.
According to TipRanks.com, Nash is a 4-star analyst with an average return of 7.7% and a 41.3% success rate. Nash covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Adverum Biotechnologies, and CymaBay Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $90.88 average price target, representing a 97.5% upside. In a report issued on November 28, H.C. Wainwright also maintained a Buy rating on the stock with a $125 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.05 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 1.15M.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
